Sight Sciences Announces 1,000th TearCare® Customer Installation
January 26, 2023 08:30 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions...
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
January 09, 2023 16:20 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions...
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
December 08, 2022 08:30 ET
|
Sight Sciences, Inc.
DATA PRESENTED AT THE 2022 AMERICAN ACADEMY OF OPTOMETRY MEETINGMEIBOMIAN GLAND FUNCTION IMPROVES BY 63% AND DRY EYE SYMPTOMS REDUCED BY 44% THROUGH 12 MONTHS MENLO PARK, Calif., Dec. 08, 2022 ...
Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 08:30 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences Reports Third Quarter 2022 Financial Results
November 10, 2022 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
November 03, 2022 08:30 ET
|
Sight Sciences, Inc.
Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery.Despite glaucoma medications and prior microbypass stenting, target IOP may no...
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
October 20, 2022 17:20 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)
September 29, 2022 08:30 ET
|
Sight Sciences, Inc.
Randomized, controlled clinical trial data on advanced dry eye patients from the OLYMPIA trial recently published in Clinical OphthalmologyStudy authors concluded that the TearCare procedure delivered...
Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting
September 28, 2022 08:30 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI...
Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting
September 16, 2022 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. announced today that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European...